• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用体外沉淀试验结合体内模拟和计算模型预测狗体内的地尔硫䓬沉淀及口服药代动力学。

Forecasting gastrointestinal precipitation and oral pharmacokinetics of dantrolene in dogs using an in vitro precipitation testing coupled with in silico modeling and simulation.

机构信息

Pharmaceutical Research and Technology Labs, Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka 425-0072, Japan; Institute of Pharmaceutical Technology, Goethe University Frankfurt am Main, Max von Laue Straβe 9, D-60438 Frankfurt am Main, Germany.

Institute of Pharmaceutical Technology, Goethe University Frankfurt am Main, Max von Laue Straβe 9, D-60438 Frankfurt am Main, Germany.

出版信息

Eur J Pharm Biopharm. 2017 Oct;119:107-113. doi: 10.1016/j.ejpb.2017.06.012. Epub 2017 Jun 13.

DOI:10.1016/j.ejpb.2017.06.012
PMID:28619610
Abstract

The aim of the current research was to determine the precipitation kinetics of dantrolene sodium using canine biorelevant in vitro testing and to model the precipitation kinetics by appropriately coupling the data with an in silico tool adapted for dogs. The precipitation profiles of dantrolene sodium solutions were obtained with the in vitro paddle apparatus at a revolution rate of 50rpm. The in silico prediction tool was designed using STELLA software and the predicted plasma concentration profiles of dantrolene using the in vitro precipitation data were compared with the observed in vivo pharmacokinetics in beagle dogs. The plasma profiles of dantrolene, which served as a model weakly acidic drug which precipitates in the upper gastrointestinal tract, was successfully predicted using the in vitro precipitation testing coupled with the in silico modeling and simulation approach. The approach was subsequently used to forecast the effect of pharmaceutical excipients (HPMC/PG) on the ability of the drug to supersaturate in the gut and the resulting pharmacokinetics. The agreement of the simulated pharmacokinetics with the observed values confirms the ability of canine biorelevant media to predict oral performance of enhanced dosage forms in dogs.

摘要

本研究旨在使用犬生物相关的体外试验来确定硝苯地平的沉淀动力学,并通过适当将数据与为犬类设计的计算工具相结合来对沉淀动力学进行建模。采用桨式装置在 50rpm 的转速下获得硝苯地平溶液的沉淀曲线。使用 STELLA 软件设计了计算预测工具,并将使用体外沉淀数据预测的硝苯地平的血浆浓度曲线与比格犬的体内药代动力学观察结果进行了比较。硝苯地平的血浆浓度曲线作为模型弱酸性药物在上胃肠道中沉淀,成功地使用体外沉淀试验与计算建模和模拟方法进行了预测。该方法随后用于预测药物赋形剂(HPMC/PG)对药物在肠道中过饱和能力的影响及其随后的药代动力学。模拟药代动力学与观察值的一致性证实了犬生物相关介质能够预测增强剂型在犬中的口服性能。

相似文献

1
Forecasting gastrointestinal precipitation and oral pharmacokinetics of dantrolene in dogs using an in vitro precipitation testing coupled with in silico modeling and simulation.运用体外沉淀试验结合体内模拟和计算模型预测狗体内的地尔硫䓬沉淀及口服药代动力学。
Eur J Pharm Biopharm. 2017 Oct;119:107-113. doi: 10.1016/j.ejpb.2017.06.012. Epub 2017 Jun 13.
2
An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.一种预测弱酸性盐口服药代动力学特征的体外-计算-体内研究方法:以丹曲林钠为例。
Eur J Pharm Biopharm. 2013 May;84(1):200-7. doi: 10.1016/j.ejpb.2012.12.001. Epub 2012 Dec 20.
3
PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations.基于生理相关溶解的 PBPK 模型预测无定形固体分散体配方的口服性能。
Eur J Pharm Sci. 2019 Jul 1;135:83-90. doi: 10.1016/j.ejps.2019.05.013. Epub 2019 May 22.
4
Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.在禁食状态下,小肠中的沉淀可能在难溶性弱碱性药物的体内性能中发挥更重要的作用:以奈非那韦为例。
Eur J Pharm Biopharm. 2011 Oct;79(2):349-56. doi: 10.1016/j.ejpb.2011.04.005. Epub 2011 Apr 18.
5
Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.采用体外-计算机模拟-体内方法预测升高胃 pH 值条件下弱碱性药物口服吸收的变化:案例研究——双嘧达莫、普拉格雷和奈非那韦。
J Pharm Sci. 2019 Jan;108(1):584-591. doi: 10.1016/j.xphs.2018.11.008. Epub 2018 Nov 10.
6
Prediction of the precipitation profiles of weak base drugs in the small intestine using a simplified transfer ("dumping") model coupled with in silico modeling and simulation approach.使用简化转运(“倾卸”)模型结合计算机模拟和仿真方法预测弱碱性药物在小肠中的沉淀曲线。
Eur J Pharm Biopharm. 2016 Jun;103:95-103. doi: 10.1016/j.ejpb.2016.03.020. Epub 2016 Mar 21.
7
Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.模拟空腹状态下近犬胃肠道的溶解介质。
Eur J Pharm Biopharm. 2013 Aug;84(3):633-41. doi: 10.1016/j.ejpb.2013.01.010. Epub 2013 Feb 19.
8
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.预测人体口服米氮平和纳米阿瑞匹坦制剂的体内吸收和食物效应。
Eur J Pharm Biopharm. 2010 Sep;76(1):95-104. doi: 10.1016/j.ejpb.2010.05.009. Epub 2010 Jun 1.
9
Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.采用体内-体外-体内模拟方法理解肠溶片剂的体内性能:案例分析双氯芬酸。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1337-47. doi: 10.1016/j.ejpb.2013.09.009. Epub 2013 Sep 18.
10
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.计算机模拟方法评价泊沙康唑的胃肠道溶出度、过饱和度和沉淀。
Mol Pharm. 2017 Dec 4;14(12):4321-4333. doi: 10.1021/acs.molpharmaceut.7b00396. Epub 2017 Sep 5.

引用本文的文献

1
Dissolution Profiles of Poorly Soluble Drug Salts in Bicarbonate Buffer.难溶性药物盐在碳酸氢盐缓冲液中的溶解曲线。
Pharm Res. 2023 Apr;40(4):989-998. doi: 10.1007/s11095-023-03508-x. Epub 2023 Apr 6.
2
Lost in modelling and simulation?迷失在建模与仿真中?
ADMET DMPK. 2021 Mar 22;9(2):75-109. doi: 10.5599/admet.923. eCollection 2021.
3
A STELLA simulation model for in vitro dissolution testing of respirable size particles.用于可吸入粒径体外溶出试验的 STELLA 模拟模型。
Sci Rep. 2019 Dec 6;9(1):18522. doi: 10.1038/s41598-019-55164-0.